Clinical Trial Update: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis [Phase 1, Phase 2]

View source ↗

Summary

An ongoing phase 1/phase 2 trial assessing the safety and efficacy of NEO212 in patients with diffuse astrocytoma (IDH-mutant), glioblastoma (IDH-wildtype), or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Diffuse Astrocytoma Idh-mutant
• Glioblastoma Idh-wildtype

Drugs mentioned

• NEO212

Snippet

Sponsor: Neonc Technologies, Inc. | Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype | Phase 1, Phase 2 | Status: RECRUITING